Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.

CKD progression Chronic kidney disease (CKD) PH1 eGFR slope eGFR trajectory estimated glomerular filtration rate (eGFR) kidney failure kidney stone nephrocalcinosis plasma oxalate primary hyperoxaluria (PH) renal function surrogate end point urinary oxalate

Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
09 2022
Historique:
received: 18 06 2021
accepted: 14 01 2022
pubmed: 21 3 2022
medline: 25 8 2022
entrez: 20 3 2022
Statut: ppublish

Résumé

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder of glyoxylate metabolism that results in early-onset kidney stone disease, nephrocalcinosis, and kidney failure. There is an unmet need for reliable markers of disease progression to test effectiveness of new treatments for patients with PH. In this study, we assessed the rate of estimated glomerular filtration rate (eGFR) decline across chronic kidney disease (CKD) glomerular filtration rate (GFR) categories (CKD G2-G5) in a cohort of patients with PH1. Retrospective observational study. Patients with PH1 enrolled in the Rare Kidney Stone Consortium (RKSC) registry who did not have kidney failure at diagnosis and who had at least 2 eGFR values recorded from within 1 month of diagnosis until their last contact date or incident kidney failure event. CKD GFR category, baseline patient and laboratory characteristics. Annualized rate of eGFR decline. Generalized estimating equations and linear regression were used to evaluate the associations between CKD GFR category, baseline patient and laboratory characteristics, and annual change in eGFR during follow-up. Compared with the slope in CKD G2 (-2.3 mL/min/1.73 m Data at regular time points were not available for all patients due to reliance on voluntary reporting in a retrospective rare disease registry. The eGFR decline was not uniform across CKD GFR categories in this PH1 population, with a higher rate of eGFR decline in CKD G3b and G4. Thus, CKD GFR category needs to be accounted for when analyzing eGFR change in the setting of PH1.

Identifiants

pubmed: 35306035
pii: S0272-6386(22)00531-5
doi: 10.1053/j.ajkd.2022.01.428
pmc: PMC9398980
mid: NIHMS1823300
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

373-382

Subventions

Organisme : NCATS NIH HHS
ID : R21 TR003174
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK083908
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK100227
Pays : United States

Informations de copyright

Copyright © 2022 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Références

J Am Soc Nephrol. 2019 Sep;30(9):1735-1745
pubmed: 31292197
Kidney Int. 2009 Jun;75(12):1264-1271
pubmed: 19225556
Kidney Int. 2009 Oct;76(7):767-73
pubmed: 19571789
Nephrol Dial Transplant. 2003 Feb;18(2):273-9
pubmed: 12543880
Nephrol Dial Transplant. 2016 May;31(5):798-806
pubmed: 26932693
Kidney Int. 2004 Nov;66(5):2032-7
pubmed: 15496176
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71
pubmed: 21586725
Clin Biochem. 2017 Dec;50(18):1014-1019
pubmed: 28764885
J Nucl Cardiol. 2019 Apr;26(2):391-393
pubmed: 30719655
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26
pubmed: 26656319
N Engl J Med. 2021 Apr 1;384(13):1216-1226
pubmed: 33789010
Front Psychol. 2017 Apr 07;8:456
pubmed: 28439244
Kidney Int. 1999 Jul;56(1):268-74
pubmed: 10411702
J Am Soc Nephrol. 2019 Sep;30(9):1746-1755
pubmed: 31292199
J Am Soc Nephrol. 2015 Oct;26(10):2559-70
pubmed: 25644115
Nephrol Dial Transplant. 1995;10 Suppl 8:22-3
pubmed: 8592620
Urolithiasis. 2020 Oct;48(5):377-384
pubmed: 32719990
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443777
Nephrol Dial Transplant. 1993;8(12):1333-7
pubmed: 8159301
Kidney Int Rep. 2020 Apr 13;5(6):955-958
pubmed: 32518881
Am J Nephrol. 2005 May-Jun;25(3):290-6
pubmed: 15961949
N Engl J Med. 2013 Aug 15;369(7):649-58
pubmed: 23944302
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065
pubmed: 32165440
Kidney Int. 2015 Mar;87(3):623-31
pubmed: 25229337
Nephrol Dial Transplant. 1995 Dec;10(12):2224-7
pubmed: 8808215
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
Nephrol Dial Transplant. 2022 Apr 25;37(5):869-875
pubmed: 33543760
Front Med (Lausanne). 2021 Apr 09;8:592357
pubmed: 33898474
Clin Chem. 2005 Dec;51(12):2377-80
pubmed: 16306102

Auteurs

Prince Singh (P)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.

Lisa E Vaughan (LE)

Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.

Phillip J Schulte (PJ)

Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.

David J Sas (DJ)

Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.

Dawn S Milliner (DS)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.

John C Lieske (JC)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: lieske.john@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH